Health
Drug to treat OCD could reduce hospitalisation risk in Covid patients, study in Lancet says – ThePrint
The study says antidepressant fluvoxamine could reduce the production of inflammatory molecules called cytokines that can be…
New Delhi: Fluvoxamine, an antidepressant used for the treatment of major depressive disorders and obsessive-compulsive disorder (OCD), can reduce the need for hospitalisation among high-risk Covid-19 patients, according to the results of a new clinical…
Continue Reading
-
Business17 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business20 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
General17 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips
-
Business16 hours agoHere’s what analysts expect for the BHP share price in the coming year